Prestige Consumer Healthcare Stock Forecast, Price & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 1.3% and is now trading at $36.37.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Prestige Consumer Healthcare.

Wall Street analysts have given Prestige Consumer Healthcare a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Thursday, November, 5th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.06. The company had revenue of $237.42 million for the quarter, compared to analysts' expectations of $227.43 million. Prestige Consumer Healthcare had a net margin of 15.84% and a return on equity of 13.81%. The business's quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 EPS.
View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare issued an update on its FY22 earnings guidance on Thursday, November, 5th. The company provided EPS guidance of approx $3.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.25.

7 Wall Street analysts have issued 12 month target prices for Prestige Consumer Healthcare's stock. Their forecasts range from $39.00 to $125.00. On average, they expect Prestige Consumer Healthcare's share price to reach $78.00 in the next twelve months. This suggests a possible upside of 114.5% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Nature's Sunshine Products (NATR) and Veru (VERU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.80%), Champlain Investment Partners LLC (4.84%), Wells Fargo & Company MN (3.88%), State Street Corp (3.43%), Acadian Asset Management LLC (2.76%) and Massachusetts Financial Services Co. MA (1.89%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Arrowstreet Capital Limited Partnership, BlackRock Inc., State Street Corp, Dalton Greiner Hartman Maher & Co., NN Investment Partners Holdings N.V., Cubist Systematic Strategies LLC, and Palisade Capital Management LLC NJ.
View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company, AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ , Truist Financial Corp, Great West Life Assurance Co. Can, Fisher Asset Management LLC, Jennison Associates LLC, and State of Tennessee Treasury Department.
View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $36.37.

Prestige Consumer Healthcare has a market capitalization of $1.82 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 520 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]